← All trials
NCT04666649
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 10, 2021
- Primary completion
- Apr 15, 2023
- Completion date
- Jul 1, 2023
- First posted
- Dec 14, 2020
- Last posted
- May 14, 2021
- Enrollment
- 30
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of MarylandLead sponsor
- University of MarylandReponsible party - principal investigator
- University of MarylandOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.